Author Index to Volume 9

Aarnaes, S.L., 51
Adler, M., 65
Ahluwahlia, G.S., 187
Ajello, L., 69
Aldridge, K.E., 47
Allen, S.D., 47, 59
Ampel, N.M., 7, 55
Amsterdam, D., 167
Anandi, V., 69
Ayers, L.W., 59

Baker, C.N., 139
Balows, A., 195
Barry, A.L., 11, 47, 59
Bartlett, K.H., 213
Belobraydic, K.A., 123
Bloom, J.W., 55
Bouza, E., 193
Bruckner, D.A., 219
Bryan, L.E., 207
Bwibo, N.O., 179

Chandler, F.W., 69
Cherry, J.D., 179
Chow, A.C., 213
Christensen, M.L., 245
Cimolai, N., 207
Clausz, J.C., 105
Coard, J.G., 225
Collaborative Antimicrobial Testing Group, 11
Condon, R.E., 105

Della-Latta, P., 133
Doern, G.V., 27

Edmiston, C.E., Jr., 105
Eng, R.E.K., 239
Ettenger, R.B., 179

Fields, H., 131
Flanders, R., 245
Flournoy, D.J., 123
Fuchs, P.C., 47, 59

Gelin, M., 65
Gerlach, E.H., 47, 97
Gibson, G., 79
Gill, V.J., 119
Goodpasture, H.C., 97
Gorbach, S.L., 79
Gribble, M.T., 197
Griffith, B., 225
Guthrie, P.J., 123

Hammond, G.W., 187
Hill, B.C., 139
Hoeprich, P.D., 115
Hughes, B.L., 51

Jacob, M., 69
Jacobs, F., 65
Jacobus, N.V., 79
Jones, R.N., 11, 47, 59, 97
Jorgensen, J.H., 27

Kelly, M.T., 1
Koech, D., 179
Koshi, G., 69
Krepel, C.J., 105
Kuhls, T.L., 179

Lawrence, C.H., 123
Leal, F., 33
Libertin, C.R., 33

MacDonald, R.L., 51
Maher, L.A., 27
Malotte, C.K., 219
Manduke, L., 219
Markowski, M.A., 225
Mathai, R., 69
Mayo, D.R., 225
de la Maza, L.M., 51
McCallum, N.M., 197
McDougal, L.K., 139
Merry, J.M., 115
Motte, S., 65

Nachamkin, I., 79
Neumann, C.G., 179
Nishanian, P.G., 179

O'Donnell, C., 41
Oliver, J.D., 41

Padhye, A.A., 69
Parides, G.C., 55
Peterie, J.D., 97
Peterson, E.M., 51
Pfaller, M., 59
Ponniah, J., 69
Preston, D.A., 27

Ray, C.G., 55
Redding, J.S., 27
Roberts, F.J., 129

Samel, C., 79
Sautter, R.L., 41
Sawyer, K., 79
Schechter, M.T., 197
Schryvers, A., 207
Serruys, E., 65
Shadomy, H.J., 231
Shadomy, S., 231
Shen, J.-P., 179
Silberg, S.L., 123
Silva, M., 79
Sitaram, V., 69
Skalina, D., 79
Smith, S.M., 239
Sommers, H.M., 47
Steele, L.C., 155
Stein, D.S., 33
Stiehm, E.R., 179
Stocker, S.A., 139
Stroh, E.M.D., 1
Swenson, J.M., 139

Taylor, J.S., 41
Thys, J.P., 65
Thornsberry, C., 27, 139
Tubert, T.A., 27

Wallace, R.J., Jr., 155
Wang, H., 231
Washington III, J., 135
Wieden, M.A., 7
Wiesmeier, E., 219
Williams, D., 119
Wong, J., 213
Woods, D.E., 207

© 1988 Elsevier Science Publishing Co., Inc.
52 Vanderbilt Avenue, New York, NY 10017

0732-8893/88/$03.50

Subject Index to Volume 9

A21978C
  LY146032 derived from, 79
Abscesses
  recovery of *Streptococcus* spp. from, 69
Acanthameba spp.
  corneal ulcers and, 196
Acholeplasma laidlawii
  antigen cross-reactivity with OC2FS monoclonal antibody, 207
Acinetobacter calcoaceticus ss. *Anitratus*
  aminoglycosides and ciprofloxacin against, 213
  cephalosporins against, 213
  extended spectrum betalactams and ciprofloxacin against, 213
  quinolones against, 213
  susceptibility testing and, 213
Actinomycetes
  aerobic, 155
Acquired immunodeficiency syndrome (AIDS), 195
Agar
  blood, 119, 155
  chocolate, 155
  Kimmig's, 231
  Mueller-Hinton, 155
  tryptic soy, 155
Agar dilution procedure
  and in vitro studies with oxiconazole nitrate, 231
AIDS. See Acquired immunodeficiency syndrome
Aladin automated instrument, 196
Amdinocillin
  against aminoglycoside-resistant or -susceptible gram-negative bacteria, 87
  against *Escherichia* spp., 87
  against *Klebsiella pneumoniae*, 87
  against *Serratia marcescens*, 87
  for urinary tract infections, 87
Amikacin
  against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
  against *Nocardia* spp., 155
Aminoglycosides
  and ciprofloxacin against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
  for endocarditis, 239
  gram-negative bacteria resistance to, 87
  Nocardia spp. resistance to, 156
  Streptococcus faecalis resistance to, 239
  synergy and, 239
Amoxicillin/clavulanic acid
  against *Nocardia spp.*, 155
Ampicillin
  checkerboard double dilution technique and, 239
  ciprofloxacin interaction with, 239
  Enterococcus spp. resistance to, 239
  against *Escherichia* spp., 87
  killing kinetics and, 239
  against *Klebsiella pneumoniae*, 87
  β-lactamase mediated resistance to, 27
  LY146032 compared to, 79
  against *Serratia marcescens*, 87
  against *Streptococcus* spp., 33, 239
Amputation
  split thickness graft and, 69
  subcutaneous zygomycosis and, 69
Anaerobic bacteria
  cephalosporin against, 11
  clindamycin testing against, 47
  ticarcillin/clavulanic acid testing against, 47
Antibodies
  HIV, 179, 225
  maternal to HLA-DQw3, 180
  maternal to HLA-DR4, 180
  monoclonal *Mycoplasma pneumoniae*, 207
  monoclonal OC2FS, 207
Antigens
  Chlamydia trachomatis, 219
  Mycoplasma pneumoniae membrane-associated protein, 207
  respiratory syncytial virus, 187
Antimicrobial susceptibility testing
  current problems in, 135
  of fastidious and unusual pathogens, 139
  instrumentation for, 167
  role of clinical laboratory in, 133
Aspergillus fumigatus
  oxiconazole nitrate against, 231
Aztreonam
  against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
  LY146032 testing with, 79

Bacillus cereus
  spores as cause of false positive *Legionella pneumophila* monoclonal antibody test, 123
BACTEC radiometric growth index
  Coccidioides immitis growth rate in, 7
Bacteremia
  gram-negative and cefotaxime, 97
  Serratia spp., 127, 193
Bacterial blood culture media
  Coccidioides immitis growth rate in, 7
Bacteriuria
  diagnostic criteria for in spinal cord injury, 197
Bacteroides spp.
  cefotetan against, 105
  cefoxitin against, 105
  ceftizoxime against, 105
  clindamycin testing against, 47
  metronidazole testing against, 47
  piperacillin against, 105
  ticarcillin/clavulanic acid testing against, 47

Betalactams
extended spectrum and ciprofloxacin against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
Biosafety
HIV and, 225
laboratory, 196
Blood agar
horse, 119
as *Nocardia* spp. medium, 155
pyridoxal-containing used in *Streptococcus* spp. recovery, 119
Brain heart infusion media
Coccidioides immitis growth rate in, 7
Branhamella catarrhalis
cephalosporin against, 11
Brazilian purpuric fever, 195
Bronchiolitis
respiratory syncytial virus-caused, 187, 245
Bronchoalveolar lavage fluid
Mycoplasma spp. in, 55
Ureaplasma urealyticum, in 55
Bronchopneumonia
respiratory syncytial virus-caused, 187
Broth microdilution MIC method
for *Nocardia* spp., 155

CAMP test, 196
Candida albicans
clotrimazole nitrate against, 231
econazole nitrate against, 231
miconazole nitrate against, 231
oxiconazole nitrate against, 231
Candidiasis
cutaneous, 231
Catheterization
and bacteriuria in spinal cord injury, 197
intermittent, 197
Cefaclor
against β-lactamases, 11
antimicrobial potency of, 11
cephalosporin ester superiority to, 59
Cefamandole
against *Escherichia* spp., 87
against *Klebsiella pneumoniae*, 87
against *Serratia marcescens*, 87
Cefazolin
against *Escherichia* spp., 87
against *Klebsiella pneumoniae*, 87
against *Serratia marcescens*, 87
Cefixime
Haemophilus influenzae resistance to, 27
Cefonicid
Haemophilus influenzae resistance to, 27
Cefoperazone
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
Cefotaxime
desacetyl, 97
dosing intervals and, 97
against gram-negative bacteremia, 97
Haemophilus influenzae resistance to, 27
serum creatinine and, 97
trough levels of, 97
Cefotetan
against *Bacteroides* spp., 105
against *Clostridium* spp., 105
against *Enterobacteriaceae* spp., 105
against *Fusobacterium* spp., 105
against *Staphylococcus* spp., 105
against streptococcal isolates, 105
against surgical microbial isolates, 105
Cefoxitin
against *Bacteroides* spp., 105
against *Escherichia* spp., 87
against *Fusobacterium* spp., 106
against *Klebsiella pneumoniae*, 87
against *Serratia marcescens*, 87
against *Staphylococcus* spp., 105
against streptococcal isolates, 105
against surgical microbial isolates, 105
Cefsulodin
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
Ceftazidime
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
Haemophilus influenzae resistance to, 27
Ceftizoxime
against *Bacteroides* spp., 105
against *Enterobacteriaceae* spp., 105
against *Fusobacterium* spp., 105
Haemophilus influenzae resistance to, 27
against *Staphylcoccus* spp., 105
against streptococcal isolates, 105
against surgical microbial isolates, 105
Ceftriaxone
Haemophilus influenzae resistance to, 27
LY146032 testing with, 79
Cefuroxime
against plasma-mediated β-lactamases, 11
Haemophilus influenzae resistance to, 27
Cell culture
for respiratory syncytial virus detection, 187, 245
Central nervous system. See CNS
Cephalexin
antimicrobial potency of, 11
cephalosporin ester superiority to, 59
Cephalosporins
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
BMY-28100, 11
against chromosomal-mediated β-lactamases, 11
against *Enterobacteriaceae* spp., 11
esters, 59
extended spectrum, 213
gram-negative bacteria against, 97
Haemophilus influenzae resistance to, 27
against *Nocardia* spp., 155
against plasma-mediated β-lactamases, 11
Cephalosporinases, Type I
against cephalosporin, 11
Cephradine
cephalosporin ester superiority to, 59
Checkerboard agar dilution technique
and *Acinetobacter calcoaceticus* ss. *Anitratus* susceptibility testing, 213
combining of ciprofloxacin with ampicillin or vancomycin and, 239
Chlamidiazyme assay
for detection of *Chlamydia trachomatis* , 219
Chlamydia trachomatis
antigen, 219

Chlamidiazyme assay for detection of, 219
direct fluorescent antibody technique for detection of, 219
ELISA assays for detection of, 219
IDEIA assay for detection of, 219
tissue culture techniques for detection of, 219
Chloramphenicol
Haemophilus influenzae resistance to, 27
Chocolate agar
as *Nocardia* spp. medium, 155
Chronic fatigue syndrome, 195
Ciprofloxacin
and aminoglycosides against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
ampicillin interaction with, 239
checkerboard double dilution technique and, 239
DNA gyrase and, 239
and extended spectrum betalactams against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
against *Haemophilus influenzae*, 27
killing kinetics and, 239
LY146032 compared to, 79
against *Nocardia* spp., 155
against *Streptococcus faecalis*, 239
vancomycin interaction with, 239
Citrobacter diversus
cephalosporin against, 11
Clavulanic acid
against *Bacteroides* spp., 47
Clindamycin
against *Bacteroides* spp., 47
against *Clostridium* spp., 79
against *Peptostreptococcus* spp., 79
LY146032 compared to, 79
Clostridium spp.
cefotetan against, 105
clindamycin against, 79
LY146032 against, 79
against penicillin, 79
piperacillin against, 105
Clotrimazole nitrate
against *Candida albicans*, 231
CNS
sulfonamide therapy for disease of, 156
Coactin. *See* Amdinocillin
Coccidioides immitis
fungemia, 7
growth discrepancies in different media, 7
Coccidioidomycosis
experimental murine, 115
recombinant human IL-2 effect in, 115
Corneal ulcers
Acanthameba spp. and, 196
Cryptococcus neoformans
oxiconazole nitrate against, 231
Cryptosporidium spp.
cysts, 196

Dermatophytes
oxiconazole nitrate against, 231
Difloxacin
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
Dilution susceptibility method
for *Nocardia* spp., 155
Direct immunofluorescent monoclonal antibody test
for detection of *Chlamydia trachomatis*, 219
false positive *Legionella pneumophila*, 123
Disk diffusion testing
for *Nocardia* spp., 155
DNA
gyrase, 239
probe detection methods, 207
Dosing intervals
cefotaxime and, 97
IL-2 and, 115
Doxycycline
against *Nocardia* spp., 155
Dysuria
acute, 198

Econazole nitrate
against *Candida albicans*, 231
against *Epidermophyton flocossum*, 231
against *Exophiala werneckii*, 231
compared to *Malassezia furfur*, 231
against *Microsporum* spp., 231
compared to oxiconazole nitrate, 231
against *Trichophyton* spp., 231
Endocarditis
aminoglycosides for, 239
ampicillin for, 239
enterococcal, 239
Streptococcus faecalis and, 239
vancomycin for, 239
Entamoeba bistolytica
trophozoites of, 196
Enterobacteriaceae spp.
cephalosporin against, 11
cephalosporin esters against, 11
cefotaxime against, 97
cefotetan against, 105
ceftizoxime against, 105
Enterococcus spp.
ampicillin resistance and, 239
cephalosporin esters against, 59
endocarditis and, 239
LY146032 against, 79
methicillin resistant strains of, 80
Enzyme immunoassay (EIA)
for HIV, 225
and false positive HIV-1 results, 179
for respiratory syncytial virus, 245
Enzyme-linked immunosorbent assay (ELISA)
for respiratory syncytial virus, 187
Epidermophyton flocossum
econazole nitrate against, 231
ketoconazole nitrate against, 231
oxiconazole nitrate against, 231
Erlichia, 195
Escherichia spp.
amdinocillin against, 87
ampicillin against, 87
cefamandole against, 87
cefazolin against, 87
cefotaxime against, 97
cefoxitin against, 87
cephalosporin against, 11
cephalosporin esters against, 59
piperacillin against, 87
ticarcillin against, 87
Exophiala werneckii
econazole nitrate against, 231
ketoconazole nitrate against, 231
oxiconazole nitrate against, 231

Fever
subcutaneous zygomycosis and, 69
Fifth disease, 195
Flagella
peritrichous, 196
Flank pain
bacteriuria and, 197
Fluorescence
in *Bacillus cereus* cultures, 123

Fungemia
Coccidiodes immitis, 7
Fusobacterium spp.
against cefotetan, 105
cefoxitin against, 105
ceftizoxime, 105
piperacillin against, 105

Gastroenteritis
Vibrio spp. and, 41
Gentamicin
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
resistance in *Serratia* spp. isolates, 193
resistance in *Streptococcus faecalis*, 239
Giardia lamblia
trophozoites of, 196
Gram-negative bacteria
amdinocillin against, 87
bacteriuria and, 197
cefotaxime for, 97
cephalosporins against, 97
Gram-positive bacteria
bacteriuria and, 197
LY146032 against, 79

Haemophilus influenzae
cephalosporin against, 11
resistance to antimicrobial agents, 27
Heat treatment
effect of on HIV antibody testing, 225
Hepadna viruses
study of, 131
Herpes simplex virus
detection of via MRC-5 shell detection method, 51
HIV. See Human Immunodeficiency virus
HIV-1. See Human immunodeficiency virus type 1
HSV. See Herpes simplex virus
HTLV-IV. See Human T lymphotropic virus type IV
Human immunodeficiency virus (HIV)
biosafety and, 225
enzyme immunoassay for, 225
heat treatment effect on antibody testing, 225
reverse transcriptase and, 225
Human immunodeficiency virus type 1 (HIV-1)
false positive serologic testing of in Kenya, 179
Human T lymphotropic virus type IV (HTLV-IV)
and false positive HIV-1 results, 179
Hyphae
zygomycete, 69
Hyphomycetes
dematiaceous, 231

IDEIA assay
for detection of *Chlamydia trachomatis*, 219
Imidazoles
oxiconazole nitrate compared to, 231
Imipenem
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
against *Legionella* pneumonia, 65
LY146032 compared to, 79
Immunofluorescent antibody test (IFA)
for diagnosis of respiratory syncytial virus, 187
Indirect fluorescent antibody (FA) technique
for respiratory syncytial virus detection, 245
Inflammation
subcutaneous zygomycosis and, 69
Instrumentation
for antimicrobial susceptibility testing, 167
Interleukin-2 (IL-2)
recombinant human in coccidiomycosis, 115

Kawasaki syndrome, 195
Ketoconazole nitrate
against *Epidermophyton flocossum*, 231
against *Exophiala werneckii*, 231
against *Malassezia furfur*, 231
compared to oxiconazole nitrate, 231
Killing kinetics
combining of ciprofloxacin with ampicillin or vancomycin and, 239
Kimmig's agar
and in vitro studies with oxiconazole nitrate, 231
Klebsiella spp.
ampicillin against, 87
cefamandole against, 87
cefazolin against, 87
cefoxitin against, 87
cefotaxime against, 97
against cephalosporin, 11
cephalosporin against, 11
K1 enzymes, 11
ticarcillin against, 87

β-Lactamase
amdinocillin and, 87
against cephalosporin, 11
chromosomal-mediated, 11
clavulanic acid inhibition of, 47
HMS, 11
and *Nocardia* spp., 155, 156
OXA, 11
plasma-mediated, 11
SHV, 11
surgical isolates and, 105
TEM, 11
Legionella pneumonia
imipenem for, 65
Legionella pneumophila
false positive direct immunofluorescent monoclonal antibody test, 123
Life expectancy
spinal cord injury and, 197
Listeria monocytogenes
cephalosporin against, 11
Lower respiratory tract infection
respiratory syncytial virus-caused, 187, 245
LY146032
compared to other antimicrobial agents, 79
against *Clostridium* spp., 79
against *Enterococcus* spp., 79
against gram-positive bacteria, 79
against *Peptostreptococcus* spp., 79
against *Staphylococcus* spp., 79
Lyme disease, 195
Lymphocytes
HLA-DQw3 phenotype, 179
HLA-DR4 phenotype, 179

Macrobroth dilution method
and streptococcal penicillin tolerance, 33
Malaria
recurrent, 180
Malassezia furfur
econazole nitrate against, 231
ketoconazole nitrate against, 231
oxiconazole nitrate against, 231
Mecillinam. See Amdinocillin
Metabolites
cefotaxime desacetyl, 97
Methicillin
-resistant *Enterococcus* spp.
-resistant *Staphylococcus* spp.
-susceptible

Staphylococcus spp., 11
Metronidazole
against *Bacteroides* spp., 47
LY146032 compared to, 79
Mezlocillin
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
Miconazole nitrate
against *Candida albicans*, 231
Microbiology
clinical and pathogenic, 195
Microsporum spp.
econazole nitrate against, 231
Minimal inhibitory concentration (MICs)
amoxycillin/clavulanate, 27
ampicillin, 27, 79
antimicrobial susceptibility testing and, 167
cephalosporin, 11
cephalosporin esters, 59
cefotaxime, 97
ciprofloxacin, 79
definition of, 167
desacetyl cefotaxime, 97
econazole nitrate, 231
Enterococcus spp., 79
imipenem, 79
ketaconazole nitrate, 231
LY146032, 79
oxiconazole nitrate, 231
penicillin, 33
ticarcillin, 47
vancomycin, 79
Minimum antibiotic concentration (MAC)
definition of, 167
Minimum bactericidal concentration (MBC)
antimicrobial susceptibility testing and, 167
Morphological change
antimicrobial susceptibility testing and, 167
Moxalactam
Haemophilus influenzae resistance to, 27
MRC-5 shell detection method for herpes simplex virus, 51
Mueller-Hinton media
Nocardia spp. growth in, 155
and streptococcal susceptibility testing against penicillin, 33
cation-supplemented, 33, 79
susceptibility testing and, 139
LY146032 tested against gram-positive bacteria in, 79
unsupplemented, 79
Mycoplasma spp.
antigen cross-reactivity with OC2FS monoclonal antibody, 207
in bronchoalveolar lavage fluid, 55
culture-amplified immunological detection of, 207
membrane-associated protein antigen, 207
monoclonal antibodies to, 207
serum cold agglutinins and, 207
sputum specimens and, 207
Mycoses
superficial, 231

Nasopharyngeal aspirates
for respiratory syncytial virus detection, 187, 245
NCCLS method
for *Nocardia* spp., 155
for testing clinically significant bacteria, 139
Necrosis
subcutaneous zygomycosis and, 69
Neisseria spp.
cephalosporin against, 11
Neufeld quellung reaction
to pneumococci, 196
Neurogenic bladder, 198
Nocardia spp.
allergy to sulfonamides and TMP/SMX, 156
aminoglycoside resistance and, 156
broth microdilution MIC method for, 155
cephalosporins against, 155
disk diffusion testing for, 155
β-lactamase resistance and, 156
NCCLS method for, 155
sulfonamide therapy for, 156
susceptibility testing of, 155
Nocardiosis
disseminated, 156
pulmonary, 156
Nosocomial infections
multidrug *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
respiratory syncytial virus and, 245

Olive oil
and in vitro studies with oxiconazole nitrate, 231
Oxacillin
against *Staphylococcus* spp., 79
LY146032 compared to, 79
Oxiconazole nitrate
agar dilution procedure and, 231
susceptibility testing and, 231
compared to econazole nitrate, 231
compared to ketoconazole nitrate, 231

Pathogens
susceptibility testing of fastidious and unusual, 139
Perfloxacin
against *Haemophilus influenzae*, 27
Penicillin
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
against *Clostridium* spp., 79
extended spectrum, 213
against *Peptostreptococcus* spp., 79
against *Streptococcus* spp., 33
LY146032 compared to, 79
Peptostreptococcus spp.
clindamycin against, 79
penicillin against, 79
LY146032 against, 79
Piperacillin
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
against *Bacteroides* spp., 105
against *Clostridium* spp., 105
against *Escherichia coli*, 87
against *Fusobacterium* spp., 105
against *Staphylococcus* spp., 105
against streptococcal isolates, 105
against surgical microbial isolates, 105
Pityriasis (tinea) versicolor, 231
Pneumococcus spp.
Neufeld quellung reaction to, 196
Pneumonia
community-acquired atypical, 207
respiratory syncytial virus-caused, 245
Post-antibiotic effect (PAE)
definition of, 167

Pregnancy
and HLA series maternal antibodies, 180
split thickness graft and, 69
Proteus mirabilis
cephalosporin against, 11
peritrichous flagella of, 196
Pseudomonas spp.
cephalosporin esters against, 59
Pulmonary disease
sulfonamide therapy for, 156
Pyelonephritis
acute, 198
Pyridoxal hydrochloride
-containing blood agar used in recovery of *Streptococcus* spp., 119

Quinolones
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
against *Haemophilus influenzae*, 27
against *Streptococcus faecalis*, 239

Radiometric growth index
Coccidioides immitis growth rate and, 7
Respiratory syncytial virus
antigens, 187
as cause of bronchiolitis, 187, 245
as cause of bronchopneumonia, 187
cell culture for detection of, 245
diagnosis of, 187
enzyme immunoassay test, 245
immunofluorescent antibody test, 187, 245
as cause of lower respiratory tract infection, 187
nosocomial infections and, 245
pneumonia and, 245
ribavarin against, 187, 245
Reverse transcriptase
HIV and, 225
Ribavarin
against respiratory syncytial virus, 187, 245
Rifampin
against *Haemophilus influenzae*, 27

Sabouraud's dextrose agar
and in vitro studies with oxiconazole nitrate, 231
Saksenaea vasiformis
as cause of zygomycosis, 69
Saline
corneal ulcers and, 196
Salmonella spp.
cephalosporin against, 11
transmission of, 196
SCH-34343
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
Sepsis
gram-negative, 98
Seroprevalence rates
HIV in rural Africa, 179
Serratia spp.
amdinocillin against, 87
ampicillin against, 87
bacteremia, 127, 193
cefamandole against, 87
cefotaxime against, 97
cefoxitin against, 87
gentamicin resistance in, 193
ticarcillin against, 87
Serum cold agglutinins
Mycoplasma pneumoniae and, 207
Sexually transmitted disease. See specific diseases
Serum creatinine
cefotaxime and, 97
Shigella spp.
transmission of, 196
Simian T lymphotropic virus type III ($STLV\text{-}III_{AGM}$)
and false positive HIV-1 results, 179
Sinuses, multiple draining
subcutaneous zygomycosis and, 69
Spinal cord injury
bacteriuria and, 197
life expectancy and, 197
Split thickness graft
amputation and, 69
potassium iodide and, 69
Sporangia
zygomycete, 69
Spores
Bacillus cereus as cause of false positive *Legionella pneumophila* monoclonal antibody test, 123
Sputum specimens
and detection of *Mycoplasma pneumoniae*, 207
Standardized disk diffusion method
for testing clinically significant bacteria, 139
Staphylococcus spp.
cefotetan against, 105
cefoxitin against, 105
ceftizoxime against, 105
cephalosporin against, 11
cephalosporin esters against, 59
LY146032 against, 79
methicillin resistant strains, 79
methicillin susceptible strains, 11
oxacillin against, 79
piperacillin against, 105
$STLV\text{-}III_{AGM}$. See Simian T lymphotropic virus type III
Streptococcus spp.
ampicillin against, 33
beta hemolytic, 119
cefotetan against, 105
cefoxitin against, 105
ceftizoxime against, 105
cephalosporin against, 11
cephalosporin esters against, 59
ciprofloxacin against, 239
Group A, 119
Group C, 11
Group D, 59
Group G, 11, 59
nutritionally deficient, 119
penicillin against, 33
piperacillin against, 105
pyridoxal-containing blood agar used in recovering, 119
vancomycin against, 239
Sulfonamide
Nocardia spp. allergy to, 156
therapy for pulmonary disease, 156
Subrapubic aspirates
for diagnosis of bacteriuria, 197
Suprapubic pain
bacteriuria and, 197
Surgical microbial isolates
in vitro β-lactamase against, 105

Tetracycline
against *Haemophilus influenzae*, 27
Ticarcillin
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
against *Escherichia* spp., 87
against *Klebsiella pneumoniae*, 87
against *Serratia marcescens*, 87
Ticarcillin/clavulanic acid
against *Bacteroides* spp., 47
Tissue culture techniques
for detection of *Chlamydia trachomatis*, 219
TMP/SMX
Nocardia spp. allergy, 156

Tobramycin
against *Acinetobacter calcoaceticus* ss. *Anitratus*, 213
LY146032 testing with, 79
Todd-Hewitt broth
and streptococcal susceptibility testing against penicillin, 33
Toxic shock syndrome, 195
Tracheal secretions
for rapid diagnosis of respiratory syncytial virus, 187
Trichophyton spp.
econazole nitrate against, 231
oxiconazole nitrate against, 231
Trimethoprim/sulfamethoxazole
Haemophilus influenzae resistance to, 27
Trophozoites
of *Entamoeba bistolytica*, 196
of *Giardia lamblia*, 196
Trough serum
cefotaxime bactericidal titers, 97
inhibitory activity, 97
Tryptic soy broth
Coccidioides immitis growth rate in, 7
Nocardia spp. growth in, 155
Trypticase soy broth
Coccidioides immitis growth rate in, 7
Tryptose phosphate broth
and streptococcal susceptibility testing against penicillin, 33
Tween, 80
and in vitro studies with oxiconazole nitrate, 231

Ultrastructural change
antimicrobial susceptibility testing and, 167
Ureaplasma urealyticum
in bronchoalveolar lavage fluid, 55
Urethral syndrome
acute, 195
Urinary tract infections
amdinocillin for, 87
bacteriuria and, 197
in spinal cord injury, 197

Vancomycin
checkerboard double dilution technique and, 239
ciprofloxacin interaction with, 239
killing kinetics and, 239
LY146032 compared to, 79
against *Streptococcus faecalis*, 239
Vibrio spp.
gastroenteritis and, 41
oysters as source of, 1
wound infection and, 41

Water temperature
oyster harvesting and, 1
Western blot analysis
for HIV, 225
for HIV-1 seropositivity, 179
Wounds
Streptococcus spp. recovery, 119
Vibrio spp. recovery from, 41

Yersinia spp.
gram stain of, 195
occurrence of, 196

Zygomycetes
hyaline hyphae of, 69
vase-shaped sporangia of, 69
Zygomycosis
Saksenaea vasiformis-caused, 69